Your browser doesn't support javascript.
loading
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Eggermont, Alexander M M; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Céleste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Konto, Cyril; Hoos, Axel; de Pril, Veerle; Gurunath, Ravichandra Karra; de Schaetzen, Gaetan; Suciu, Stefan; Testori, Alessandro.
Afiliación
  • Eggermont AM; Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. Electronic address: alexander.eggermont@gustaveroussy.fr.
  • Chiarion-Sileni V; IOV-IRCCS, Melanoma Oncology Unit, Padova, Italy.
  • Grob JJ; Aix-Marseille University, Hôpital de La Timone APHM, Marseille, France.
  • Dummer R; University of Zürich Hospital, Zürich, Switzerland.
  • Wolchok JD; Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
  • Schmidt H; Aarhus University Hospital, Aarhus, Denmark.
  • Hamid O; The Angeles Clinic and Research Institute, Los Angeles, CA, USA.
  • Robert C; Gustave Roussy Cancer Campus Grand Paris, Villejuif, France.
  • Ascierto PA; Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy.
  • Richards JM; Oncology Specialists SC, Park Ridge, IL, USA.
  • Lebbé C; Assistance Publique Hôpitaux de Paris, Dermatology and CIC Departments, Hôpital Saint Louis, University Paris 7, INSERM U976, France.
  • Ferraresi V; Istituti Fisioterapici Ospitalieri, Rome, Italy.
  • Smylie M; Cross Cancer Institute, Edmonton, Alberta, Canada.
  • Weber JS; H Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Maio M; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
  • Konto C; Bristol-Myers Squibb, Wallingford, CT, USA.
  • Hoos A; Bristol-Myers Squibb, Wallingford, CT, USA.
  • de Pril V; Bristol-Myers Squibb, Braine-l'Alleud, Belgium.
  • Gurunath RK; EORTC Headquarters, Brussels, Belgium.
  • de Schaetzen G; EORTC Headquarters, Brussels, Belgium.
  • Suciu S; EORTC Headquarters, Brussels, Belgium.
  • Testori A; European Institute of Oncology, Milan, Italy.
Lancet Oncol ; 16(5): 522-30, 2015 May.
Article en En | MEDLINE | ID: mdl-25840693
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Adyuvantes Inmunológicos / Melanoma / Anticuerpos Monoclonales / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Adyuvantes Inmunológicos / Melanoma / Anticuerpos Monoclonales / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article